114 related articles for article (PubMed ID: 38306271)
1. EZH2/G9a interact to mediate drug resistance in non-small-cell lung cancer by regulating the SMAD4/ERK/c-Myc signaling axis.
Zhang Q; Shi Y; Liu S; Yang W; Chen H; Guo N; Sun W; Zhao Y; Ren Y; Ren Y; Jia L; Yang J; Yun Y; Chen G; Wang L; Wu C
Cell Rep; 2024 Feb; 43(2):113714. PubMed ID: 38306271
[TBL] [Abstract][Full Text] [Related]
2. EZH2 inhibitors reverse resistance to gefitinib in primary EGFR wild-type lung cancer cells.
Gong H; Li Y; Yuan Y; Li W; Zhang H; Zhang Z; Shi R; Liu M; Liu C; Chen C; Liu H; Chen J
BMC Cancer; 2020 Dec; 20(1):1189. PubMed ID: 33276757
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of EZH2 and histone deacetylases as a potential epigenetic therapy for non-small-cell lung cancer cells.
Takashina T; Kinoshita I; Kikuchi J; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Nishimura M; Dosaka-Akita H
Cancer Sci; 2016 Jul; 107(7):955-62. PubMed ID: 27116120
[TBL] [Abstract][Full Text] [Related]
4. Loss of histone lysine methyltransferase EZH2 confers resistance to tyrosine kinase inhibitors in non-small cell lung cancer.
Quan C; Chen Y; Wang X; Yang D; Wang Q; Huang Y; Petersen RB; Liu X; Zheng L; Li Y; Huang K
Cancer Lett; 2020 Dec; 495():41-52. PubMed ID: 32920200
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
[TBL] [Abstract][Full Text] [Related]
6. Expression of the enhancer of zeste homolog 2 in biopsy specimen predicts chemoresistance and survival in advanced non-small cell lung cancer receiving first-line platinum-based chemotherapy.
Xu C; Hao K; Hu H; Sheng Z; Yan J; Wang Q; Yu L
Lung Cancer; 2014 Nov; 86(2):268-73. PubMed ID: 25262426
[TBL] [Abstract][Full Text] [Related]
7. EZH2 promotes malignant behaviors via cell cycle dysregulation and its mRNA level associates with prognosis of patient with non-small cell lung cancer.
Cao W; Ribeiro Rde O; Liu D; Saintigny P; Xia R; Xue Y; Lin R; Mao L; Ren H
PLoS One; 2012; 7(12):e52984. PubMed ID: 23300840
[TBL] [Abstract][Full Text] [Related]
8. Targeting histone methyltransferase G9a inhibits growth and Wnt signaling pathway by epigenetically regulating HP1α and APC2 gene expression in non-small cell lung cancer.
Zhang K; Wang J; Yang L; Yuan YC; Tong TR; Wu J; Yun X; Bonner M; Pangeni R; Liu Z; Yuchi T; Kim JY; Raz DJ
Mol Cancer; 2018 Oct; 17(1):153. PubMed ID: 30348169
[TBL] [Abstract][Full Text] [Related]
9. A central role for G9a and EZH2 in the epigenetic silencing of cyclooxygenase-2 in idiopathic pulmonary fibrosis.
Coward WR; Feghali-Bostwick CA; Jenkins G; Knox AJ; Pang L
FASEB J; 2014 Jul; 28(7):3183-96. PubMed ID: 24652950
[TBL] [Abstract][Full Text] [Related]
10. miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer.
Sun J; Cai X; Yung MM; Zhou W; Li J; Zhang Y; Li Z; Liu SS; Cheung ANY; Ngan HYS; Li Y; Dai Z; Kai Y; Tzatsos A; Peng W; Chan DW; Zhu W
Oncogene; 2019 Jan; 38(4):564-580. PubMed ID: 30166592
[TBL] [Abstract][Full Text] [Related]
11. Interplay between EZH2 and G9a Regulates CXCL10 Gene Repression in Idiopathic Pulmonary Fibrosis.
Coward WR; Brand OJ; Pasini A; Jenkins G; Knox AJ; Pang L
Am J Respir Cell Mol Biol; 2018 Apr; 58(4):449-460. PubMed ID: 29053336
[TBL] [Abstract][Full Text] [Related]
12. Chromatin remodeling by the histone methyltransferase EZH2 drives lung pre-malignancy and is a target for cancer prevention.
Tellez CS; Picchi MA; Juri D; Do K; Desai DH; Amin SG; Hutt JA; Filipczak PT; Belinsky SA
Clin Epigenetics; 2021 Feb; 13(1):44. PubMed ID: 33632299
[TBL] [Abstract][Full Text] [Related]
13. FZKA reverses gefitinib resistance by regulating EZH2/Snail/EGFR signaling pathway in lung adenocarcinoma.
Tang Q; Xu M; Long S; Yu Y; Ma C; Wang R; Li J; Wang X; Fang F; Han L; Wu W; Wang S
J Ethnopharmacol; 2024 Jan; 318(Pt A):116646. PubMed ID: 37269912
[TBL] [Abstract][Full Text] [Related]
14. Overexpression of MYC and EZH2 cooperates to epigenetically silence MST1 expression.
Kuser-Abali G; Alptekin A; Cinar B
Epigenetics; 2014 Apr; 9(4):634-43. PubMed ID: 24499724
[TBL] [Abstract][Full Text] [Related]
15. Combined Inhibition of G9a and EZH2 Suppresses Tumor Growth via Synergistic Induction of IL24-Mediated Apoptosis.
Casciello F; Kelly GM; Ramarao-Milne P; Kamal N; Stewart TA; Mukhopadhyay P; Kazakoff SH; Miranda M; Kim D; Davis FM; Hayward NK; Vertino PM; Waddell N; Gannon F; Lee JS
Cancer Res; 2022 Apr; 82(7):1208-1221. PubMed ID: 35149587
[TBL] [Abstract][Full Text] [Related]
16. Oncogenic enhancer of zeste homolog 2 is an actionable target in patients with non-small cell lung cancer.
Shi B; Behrens C; Vaghani V; Riquelme EM; Rodriguez-Canales J; Kadara H; Lin H; Lee J; Liu H; Wistuba I; Simon G
Cancer Med; 2019 Oct; 8(14):6383-6392. PubMed ID: 31456359
[TBL] [Abstract][Full Text] [Related]
17. Coordinated silencing of MYC-mediated miR-29 by HDAC3 and EZH2 as a therapeutic target of histone modification in aggressive B-Cell lymphomas.
Zhang X; Zhao X; Fiskus W; Lin J; Lwin T; Rao R; Zhang Y; Chan JC; Fu K; Marquez VE; Chen-Kiang S; Moscinski LC; Seto E; Dalton WS; Wright KL; Sotomayor E; Bhalla K; Tao J
Cancer Cell; 2012 Oct; 22(4):506-523. PubMed ID: 23079660
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA SNHG16 decreased SMAD4 to induce gemcitabine resistance in pancreatic cancer via EZH2-mediated epigenetic modification.
Yu Y; Zou YF; Hong RQ; Chen WJ; Chen L; Chen WQ; Wang HP; Yu Y
Kaohsiung J Med Sci; 2022 Oct; 38(10):981-991. PubMed ID: 36053032
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
[TBL] [Abstract][Full Text] [Related]
20. EZH2 promotes tumor progression via regulating VEGF-A/AKT signaling in non-small cell lung cancer.
Geng J; Li X; Zhou Z; Wu CL; Dai M; Bai X
Cancer Lett; 2015 Apr; 359(2):275-87. PubMed ID: 25633838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
